Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Provided By PR Newswire

Last update: Jun 30, 2025

NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS).